To investigate the role of mH2A1 in GBM tumorigenicity, we performed genome-wide mapping of mH2A1 binding using chromatin immunoprecipitation-sequencing (ChIP-Seq) in LN229/EGFRvIII cells treated with or without EGFR inhibitor erlotinib or CDK5 inhibitor Roscovitine (Fig. 7a). Here, EGFR is linked to glioblastoma.